Abbildung 24: Blutdrucksenkung - Nephropathie
The Efficacy and Safety in Patients with Renal Impairment treated with Telmisartan (ESPRIT) trial was an 8-week, open-label study of telmisartan 40–80 mg in 82 patients with hypertension (DBP 90–109 mmHg) and chronic mild/moderate (GFR 30–74 ml/min/1.73 m2) or severe renal impairment (GFR <30 ml/min/1.73 m2), or requiring maintenance haemodialysis.1 Blood pressure was significantly reduced in all groups, and there were no statistically significant between-group differences in the magnitude of the reduction. Drug-related adverse events were uncommon, and were typical class effects of ARBs. There were few notable changes in laboratory parameters following telmisartan treatment. 1. Sharma AM, et al. Telmisartan in patients with mild/moderate hypertension and chronic kidney disease. Clin Nephrol 2005; 63: 250–257.